BION-1301 is under clinical development by Chinook Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BION-1301’s likelihood of approval (LoA) and phase transition for IgA Nephropathy (Berger’s Disease) took place on 07 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BION-1301 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BION-1301 overview

BION-1301 is under development for the treatment of IgA nephropathy. It comprises of humanized IgG4 monoclonal antibody. The drug candidate targets APRIL-dependent survival in B-cell malignancies. The drug candidate is developed based on B-select antibody platform (B-select) technology. It is administered by intravenous and subcutaneous route. It was also under development for the treatment of  B-cell chronic lymphocytic lymphoma, colorectal cancer and relapsed or refractory multiple myeloma.

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

Quick View BION-1301 LOA Data

Report Segments
  • Innovator
Drug Name
  • BION-1301
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.